Insider Buys 70,000 Aldeyra Shares Amid Institutional Sell‑offs, Raising Questions About the Company’s Future Value

Insider Buying Signals a Re‑evaluation of Aldeyra’s Value On March 19, 2026, director Douglas Richard purchased 70,000 shares of Aldeyra Therapeutics at $1.40, boosting his holdings to 195,000 shares. The trade occurred when the market price was $1.81, suggesting that insiders still see upside potential even as the stock has slid sharply over the past year. Richard’s purchase, coupled with a similar buy by Chief Financial Officer Michael Alfieri a day earlier, indicates that senior management remains committed to the company’s long‑term strategy, despite recent volatility.

Contrasting Insider and Institutional Activity While insiders are buying, institutional activity tells a different story. In April 2025, Perceptive Advisors sold more than 3.4 million shares, a move that likely reflected a profit‑taking stance after a prior rally. The recent sell‑off was followed by a substantial volume of put options traded, a classic signal that large investors are hedging against a decline. The juxtaposition of insider purchases with institutional selling and bearish option positions paints a complex picture: insiders appear bullish, whereas many outside investors are wary.

Implications for Investors For the retail and institutional investors watching Aldeyra, this mix of signals is a cautionary tale. Insider buying can be a positive barometer, but it is not a guarantee of future performance—especially when the company’s fundamentals are under pressure. Aldeyra’s price‑earnings ratio remains negative at –3.673, and the stock has lost more than 60 % of its value this year. A 52‑week low of $1.07 and a market cap of only $281 million suggest that the company is still in a precarious position. Investors should therefore treat the recent insider purchases as a potential “buy the dip” opportunity rather than a definitive endorsement.

Looking Ahead: A Fragile Upside Aldeyra’s focus on ocular disease therapies remains niche, but regulatory hurdles and legal scrutiny could impede future product launches. If the company can deliver on its pipeline milestones, insider confidence may translate into tangible upside; however, the current bearish sentiment—indicated by a sentiment score of –1 and a buzz of 52.56 %—suggests that market participants are still uncertain. For those considering exposure, a cautious approach that monitors both insider activity and institutional flows will likely serve best as Aldeyra navigates its next fiscal quarter.